1. Co-delivery of resolvin D1 and antibiotics with nanovesicles to lungs resolves inflammation and clears bacteria in mice.
- Author
-
Gao J, Wang S, Dong X, Leanse LG, Dai T, and Wang Z
- Subjects
- Animals, Anti-Bacterial Agents therapeutic use, Ceftazidime therapeutic use, Docosahexaenoic Acids therapeutic use, Drug Delivery Systems, Human Umbilical Vein Endothelial Cells, Humans, Inflammation microbiology, Male, Mice, Nanostructures, Pneumonia, Bacterial, Pseudomonas Infections drug therapy, Anti-Bacterial Agents administration & dosage, Ceftazidime administration & dosage, Docosahexaenoic Acids administration & dosage, Inflammation drug therapy, Pseudomonas Infections microbiology, Pseudomonas aeruginosa
- Abstract
Resolution is an active process that protects the host damage from inflammation responses induced by infections. Simultaneously resolving inflammation and eliminating pathogens may be effective to treat infectious diseases, but it is required to deliver therapeutics to infectious sites. Here, we proposed a strategy to incorporate RvD1 and an antibiotic (ceftazidime) in human neutrophil-membrane derived nanovesicles that can specifically target inflamed vasculature for treatment of lung infection caused by P. aeruginosa. Using the nitrogen cavitation method, we generated liposome-like nanovesicles from human neutrophil membrane. The results showed that nanovesicles loaded with RvD1 decreased cytokine levels and neutrophil lung infiltration, thus shortening the resolution intervals of lung inflammation. When RvD1 and ceftazidime were co-loaded in nanovesicles, they alleviated both inflammation and bacterial growth in the mouse lung. The studies reveal a new strategy to treat infectious diseases by designing nanoparticles to simultanesouly target host inflammatory pathways and pathogens.
- Published
- 2020
- Full Text
- View/download PDF